Science Explorer Back to mapMap
Discussion
Company · Hørsholm · Denmark

Cytovac (Denmark)

cytovac.comROR OpenAlex
Research works
1
▼ 18% vs 2018-21
Citations
25
17.9 per fractional work
Top-10% rate
14.3%
all institutions 10.0%
Open access
64%
world 40%
International
16%
world 18%
Cytovac (Denmark)

Not ranked overall: Cytovac (Denmark) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Cytovac (Denmark) work in?

In all years, 54% of research at Cytovac (Denmark) is in Life Sciences, 46% in Health Sciences. Its largest fields are Immunology and Microbiology (46%), Medicine (46%), Biochemistry, Genetics and Molecular Biology (8%).

Life Sciences: 1 fractional works · 53.8% of its workImmunology and Microbiology: 1 fractional works · 46.2% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 7.7% of its workHealth Sciences: 1 fractional works · 46.2% of its workMedicine: 1 fractional works · 46.2% of its workALL ITS WORKCytovac (Denmark)1fractional works, all years
Life Sciences54%Health Sciences46%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 3 fields, with their numbers
    1. Immunology and Microbiology146.2%
    2. Biochemistry, Genetics and Molecular Biology07.7%
    1. Medicine146.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Cytovac (Denmark)?

The most cited paper from Cytovac (Denmark) is "Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells" (Alexei F. Kirkin, Karine N. Dzhandzhugazyan, Per Guldberg et al., 2018), with 52 citations. Next come "Adoptive T cell cancer therapy" (27) and "Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis" (15).

Most cited papers
#PaperReleasedCitations
1 Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells Alexei F. Kirkin, Karine N. Dzhandzhugazyan, Per Guldberg et al. · Nature Communications Open access 19 Feb 2018 52
2 Adoptive T cell cancer therapy Karine N. Dzhandzhugazyan, Per Guldberg, Alexei F. Kirkin · Nature Materials 15 May 2018 27
3 Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis Odd Lilleng Gammelgaard, Mikkel G. Terp, Alexei F. Kirkin et al. · Molecular Cancer Open access 6 Jan 2024 15
4 Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition Mie K. Jakobsen, Sofie Traynor, Aaraby Nielsen et al. · Journal of Experimental & Clinical Cancer Research Open access 23 Jan 2025 11
5 A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma Katja Werlenius, Giuseppe Stragliotto, Michael Strandéus et al. · Neuro-Oncology Advances Open access 2021 10
All 6 most cited papers, with filters and sorting

Which research topics does Cytovac (Denmark) publish most on?

By volume in 2022-now: Phagocytosis and Immune Regulation, CAR-T cell therapy research, Immunotherapy and Immune Responses and Immune cells in cancer.

Phagocytosis and Immune …0Phagocytosis and Immune Regulation: 0 fractional worksCAR-T cell therapy resea…0CAR-T cell therapy research: 0 fractional worksImmunotherapy and Immune Responses: 0 fractional worksImmune cells in cancer: 0 fractional works
ImmunologyOncology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Phagocytosis and Immune Regulation Immunology 0 works
  2. 2 CAR-T cell therapy research Oncology 0 works
  3. 3 Immunotherapy and Immune Responses Immunology 0 works
  4. 4 Immune cells in cancer Immunology 0 works
  5. 5 Genomics and Chromatin Dynamics Molecular Biology 0 works
  6. 6 Epigenetics and DNA Methylation Molecular Biology 0 works
  7. 7 Histone Deacetylase Inhibitors Research Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available64.3%not open35.7%

World: 40% of research is openly available.

with international co-authors16.1%domestic only83.9%

World: 18% is written across borders.

How has Cytovac (Denmark)'s research output changed?

Output in 2022-2025 was 18% lower than in 2018-2021.

still counting20202025

Other research institutions in Hørsholm

All research institutions in Hørsholm

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Cytovac (Denmark). Posts are plain text and can be reported.